The AutoChamber™ and AutoBMD™ AI solutions will soon be available on the Precision Imaging Network, with AI-CVD® planned for later.
Houston, TX, United States, February 3, 2026 /EINPresswire.com/- heartlung.aiThe AI-enabled company, which focuses on the early detection and prevention of heart disease, lung cancer, osteoporosis, emphysema and fatty liver disease using widely available CT scans, has announced that its AutoChamber™ and AutoBMD™ AI services will be available through the Precision Imaging Network, part of Microsoft for Healthcare. The Precision Imaging Network is a cloud-based clinical AI platform designed to accelerate the secure and scalable adoption of advanced imaging algorithms in health systems and diagnostic imaging centers. This relationship supports Heartlung.AI’s plans to introduce these solutions into the Precision Imaging Network ecosystem and help hospitals and imaging clinics deliver preventive care at scale.
HeartLung.AI’s opportunistic screening services, including AutoBMD™ and AutoChamber™, analyze CT images previously obtained for other clinical reasons so that Precision Imaging Network sites can add preventive insights without changing imaging protocols. AutoBMD detects osteoporosis and osteopenia from routine CT with DEXA-equivalent bone mineral density results, including clear T-score and Z-score, while AutoChamber™ analyzes cardiac chamber structure to characterize risk patterns associated with heart failure, stroke and atrial fibrillation, helping to expand cardiovascular insights beyond standard coronary calcium or plaque analysis. Reports are sent back into the normal radiology workflow within minutes, and services are reimbursable under applicable Medicare and commercial payer pathways, helping practices enhance preventive care while generating additional revenue.
The Precision Imaging Network is designed to accelerate clinical adoption of FDA-cleared medical imaging AI by integrating algorithms into existing radiology environments. Making AutoChamber and AutoBMD available through the Precision Imaging Network enables participating health systems and imaging centers to activate these services using a secure, PACS-connected infrastructure, streamlining onboarding, standardizing reporting, and reducing time-to-diagnostic-value.
“Preventive imaging only works if it is clinically meaningful, affordable, and scalable,” said Dr. Morteza Nagavi, founder and chief medical officer of HeartLung.ai. “AutoBMD™ and AutoChamber™ transform routine CT scans into powerful early-detection tools, helping physicians identify osteoporosis risk and subtle cardiovascular changes sooner, more consistently, and in far more patients.”
“Radiology teams need AI that fits into the way they work today,” said Vikram Chhabra, general manager of diagnostic solutions at Microsoft. “Delivering AutoBMD and AutoChamber through the Precision Imaging Network helps providers integrate preventive insights directly into existing workflows to support earlier, more consistent detection across broader patient populations.” Following the rollout of AutoChamber™ and AutoBMD™, HeartLung.AI plans to expand its footprint within the Precision Imaging Network by launching. AI-CVD®The most comprehensive opportunistic cardiovascular and multisystem CT screening platform approved by the FDA. AI-CVD® AutoChamber and AutoBMD will leverage the same imaging inputs and secure infrastructure, enabling participating sites to expand preventive insights without the need for additional deployment complexity. AI-CVD® It is expected to deliver several actionable reports targeting different aspects of cardiometabolic health.
This relationship reflects a shared focus on broadening access to high-impact imaging AI-enabled radiology teams with automated, quantitative outputs that naturally fit into clinical workflows and help catch disease earlier.
About Heartlung AI
Heartlung Corporation is a medical technology company dedicated to AI-enabled, CT-based opportunistic screening and early disease detection. HeartLung’s mission is to shift health care from early detection and prevention to end-stage disease treatment by using artificial intelligence to unlock clinically actionable information embedded within routine medical imaging.
Heartlung has developed FDA-approved AI technologies for the opportunistic detection and prevention of heart disease, lung cancer, emphysema/COPD, osteoporosis, myosteatosis, fatty liver disease and other life-threatening conditions – often years before symptoms appear.
The company has received FDA Breakthrough Device Designation and FDA 510(k) clearance for AutoChamber™, an AI-powered device that detects enlarged heart chambers and left ventricular hypertrophy on non-contrast chest CT scans, including low-dose CT used for lung cancer screening and contrast-enhanced coronary CT angiography (CCTA). Heartlung has also received FDA 510(k) clearance for AutoBMD™, the only CT-based, DEXA-equivalent opportunistic osteoporosis screening technology cleared by the FDA and reimbursed by Medicare.
These technologies are now integrated within AI-CVD®HeartLung’s flagship FDA-approved platform for large-scale opportunistic screening in the cardiovascular and multisystem disease domains. By enabling physicians to derive far greater preventive value from CT scans than ever before, Hartlung aims to redefine how imaging contributes to population health, value-based care, and early disease prevention.
For more information visit https://www.heartlung.ai
About AI-CVD®
The US Food and Drug Administration (FDA) has approved the following indications for the use of AI-CVD®: :
AI-CVD® is an opportunistic, AI-powered quantitative imaging tool that provides automated CT-derived structural and density-based measurements for physicians to review. Using AI-CVD® Using quantitative imaging measurements and clinical assessment, healthcare providers can screen patients who are unaware of their risk for:
coronary heart disease
heart failure
irregular heartbeat
stroke
osteoporosis
liver steatosis
diabetes
Other adverse health conditions that may require follow-up
Ten FDA-approved opportunistic measurement domains in a single platform
AI-CVD® Includes FDA-approved modules for:
Coronary Artery Calcium (CAC) Scoring
aortic wall calcium
aortic valve calcium
mitral valve calcium
cardiac chamber volumetry
epicardial fat volumetry
size of aorta and pulmonary artery
Lung attenuation analysis
Liver attenuation analysis
Bone Mineral Density and Muscle-Fat Composition
Built as a modular, AI-powered quantitative imaging platform, AI-CVD® Automatically extracts clinically relevant anatomic and density-based measurements from existing chest and abdominal CT scans, without additional imaging, radiation, contrast or workflow disruption.
AI-CVD® Integrates multiple FDA-approved technologies, including AutoChamber™ and AutoBMD™, into an integrated system designed for opportunistic screening and early disease detection. The platform enables physicians to identify patients who may warrant additional diagnostic testing, monitoring, or preventive action by using objective, CT-derived measurements from scans already being performed for other clinical indications.
Consistent with FDA-approved indications for use, AI-CVD® Does not provide clinical interpretation or risk prediction. Instead, it equips healthcare providers with quantitative imaging insights that transform routine CT imaging into a scalable basis for preventive care across the cardiovascular, metabolic, pulmonary, and skeletal disease domains.
Learn more here https://www.heartlung.ai/aicvd
About AutoBMD™ AI
Heartlung’s AutoBMD™ is an AI-powered, cloud-based solution for opportunistic bone mineral density measurement using existing CT scans. It is the only DEXA-equivalent, CT-based osteoporosis screening approved by the FDA, applied to more than 25 million CT scans annually and reimbursed by Medicare.
About AutoChamber™ AI
HeartLung’s AutoChamber™ is designed to work with both non-contrast and contrast-enhanced chest CT scans, providing estimation of cardiac volume, cardiac chambers volume, and left ventricular wall mass. This AI-powered tool detects cardiomegaly and enlarged individual heart chambers, including the left atrium (LA) and left ventricle (LV), which are often missed in routine scans. By identifying these conditions early, AutoChamber™ AI helps prevent life-threatening diseases like stroke, heart failure and atrial fibrillation. It has received FDA “Breakthrough Designation” for its ability to identify enlarged heart chambers and left ventricular hypertrophy in non-contrast chest CT scans.
Marlon Montes
Heartlung Technologies
+1 310-510-6004
Email us here
Visit us on social media:
Linkedin
x
legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
For the accuracy, content, images, videos, licenses, completeness, legality or reliability of the information contained herein
Article. If you have any complaints or copyright issues related to this article, please contact the author above.
The information contained on this page is provided by an independent third-party content provider. XPRMedia and this site make no warranties or representations in connection therewith. If you are associated with this page and wish to have it removed, please contact pressreleases@xpr.media
